Anticancer Activity Studies of Ruthenium(II) Complex Toward Human Osteosarcoma HOS Cells

• Published in: The Journal of membrane biology Vol. 249; no. 4; pp. 483 - 492
• Main Authors: Zhu, Jian-Wei, Liu, Si-Hong, Zhang, Gui-Qiang, Xu, Hui-Hua, Wang, Yu-Xuan, Wu, Yong, Liu, Ya-Min, Wang, Yan, Liang, Jun-Bo, Guo, Qi-Feng
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.08.2016; Springer Nature B.V
• Subjects: Animals; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Apoptosis; Apoptosis - drug effects; Biochemistry; Biomedical and Life Sciences; Bone cancer; Bone Neoplasms - drug therapy; Bone Neoplasms - metabolism; Bone Neoplasms - pathology; Cell Cycle - drug effects; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Survival; Chemotherapy; Cytotoxicity; Disease Models, Animal; Dose-Response Relationship, Drug; Human Physiology; Humans; Life Sciences; Membrane Potential, Mitochondrial - drug effects; Membranes; Mice; Molecular Structure; Organometallic Compounds - chemistry; Organometallic Compounds - pharmacology; Osteosarcoma - drug therapy; Osteosarcoma - metabolism; Osteosarcoma - pathology; Reactive Oxygen Species - metabolism; Ruthenium - chemistry; Xenograft Model Antitumor Assays; Ruthenium(II) complex; Cytotoxicity in vitro and in vivo; Cell cycle arrest; Reactive oxygen species; Apoptosis
• ISSN: 0022-2631; 1432-1424
• DOI: 10.1007/s00232-016-9889-y

A new Ru(II) complex [Ru(dmp) 2 (NMIP)](ClO 4 ) 2 (dmp = 2,9-dimethyl-1,10-phenanthroline, NMIP = 2’-(2″-nitro-3″,4″-methylenedioxyphenyl)imidazo[4′,5′- f ][1,10]-phenanthroline) was synthesized and characterized by elemental analysis, ESI–MS and 1 H NMR. The cytotoxic activity of the complex against MG-63, U2OS, HOS, and MC3T3-e1 cell lines was investigated by MTT method. The complex shows moderate cytotoxicity toward HOS (IC 50  = 35.6 ± 2.6 µM) and MC3T3-e1 (IC 50  = 41.6 ± 2.8 µM) cell lines. The morphological studies show that the complex can induce apoptosis in HOS cells and cause an increase of reactive oxygen species levels and a decrease in the mitochondrial membrane potential. The cell cycle distribution demonstrates that the complex inhibits the cell growth at S phase. Additionally, the antitumor activity in vivo reveals that the complex can induce a decrease in tumor weight.